{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T07:06:06Z","timestamp":1763535966393},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,4,26]],"date-time":"2022-04-26T00:00:00Z","timestamp":1650931200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,26]],"date-time":"2022-04-26T00:00:00Z","timestamp":1650931200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Little is known about the association between hyperuricemia and ventricular tachycardia and fibrillation (VT\/VF) in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PPCI).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The data from a cohort of STEMI patients undergoing PPCI at our center from January 2013 to December 2018 were retrospectively analyzed. The endpoint of the study was the occurrence of VT\/VF, including (1) non-sustained ventricular tachycardia (nsVT) on Holter monitoring; (2) sustained ventricular tachycardia (SVT)\/VF on cardiac monitoring.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of the 634 patients included in the study, 147 (23.2%) of them had hyperuricemia. The occurrence of VT\/VF after PPCI was significantly higher in patients with hyperuricemia (19.0 vs. 9.4%,<jats:italic>p<\/jats:italic>\u2009=\u20090.001) compared with those without hyperuricemia. Hyperuricemia was associated with a significantly higher risk of VF\/VT (odds ratio (OR) 2.11; 95% CI 1.11\u20134.03;<jats:italic>p<\/jats:italic>\u2009=\u20090.024). The strength of this association remained statistically after adjustments for age, sex, history of hypertension, estimated glomerular filtration rate, hypersensitive C reactive protein, plasma natrium, peak troponin I, fasting glucose, B-type natriuretic peptides and VT\/VF in PPCI (adjusted odds ratio 2.73; 95% CI 1.19\u20136.27;<jats:italic>p<\/jats:italic>\u2009=\u20090.018).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>There is a significant association between hyperuricemia and increased prevalence of VT\/VF in STEMI patients after PPCI, independently of multiple risk factors and potential confounders.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12872-022-02635-4","type":"journal-article","created":{"date-parts":[[2022,4,26]],"date-time":"2022-04-26T14:03:40Z","timestamp":1650981820000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Hyperuricemia is associated with an increased prevalence of ventricular tachycardia and fibrillation in patients with ST-elevation myocardial infarction after primary percutaneous coronary intervention"],"prefix":"10.1186","volume":"22","author":[{"given":"Xianqing","family":"Hu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shenwen","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saibin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,4,26]]},"reference":[{"issue":"19","key":"2635_CR1","doi-asserted-by":"publisher","first-page":"2030","DOI":"10.1161\/01.CIR.98.19.2030","volume":"98","author":"AN Cheema","year":"1998","unstructured":"Cheema AN, Sheu K, Parker M, Kadish AH, Goldberger JJ. Nonsustained ventricular tachycardia in the setting of acute myocardial infarction: tachycardia characteristics and their prognostic implications. Circulation. 1998;98(19):2030\u20136.","journal-title":"Circulation"},{"issue":"8","key":"2635_CR2","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1093\/eurheartj\/ehi188","volume":"26","author":"TH Makikallio","year":"2005","unstructured":"Makikallio TH, Barthel P, Schneider R, Bauer A, Tapanainen JM, Tulppo MP, Schmidt G, Huikuri HV. Prediction of sudden cardiac death after acute myocardial infarction: role of Holter monitoring in the modern treatment era. Eur Heart J. 2005;26(8):762\u20139.","journal-title":"Eur Heart J"},{"issue":"7","key":"2635_CR3","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1253\/circj.CJ-16-0183","volume":"80","author":"M Masuda","year":"2016","unstructured":"Masuda M, Nakatani D, Hikoso S, Suna S, Usami M, Matsumoto S, Kitamura T, Minamiguchi H, Okuyama Y, Uematsu M, et al. Clinical impact of ventricular tachycardia and\/or fibrillation during the acute phase of acute myocardial infarction on in-hospital and 5-year mortality rates in the percutaneous coronary intervention era. Circ J. 2016;80(7):1539\u201347.","journal-title":"Circ J"},{"issue":"17","key":"2635_CR4","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1001\/jama.2009.600","volume":"301","author":"RH Mehta","year":"2009","unstructured":"Mehta RH, Starr AZ, Lopes RD, Hochman JS, Widimsky P, Pieper KS, Armstrong PW, Granger CB. Incidence of and outcomes associated with ventricular tachycardia or fibrillation in patients undergoing primary percutaneous coronary intervention. JAMA. 2009;301(17):1779\u201389.","journal-title":"JAMA"},{"issue":"6","key":"2635_CR5","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/j.amjcard.2011.10.043","volume":"109","author":"RH Mehta","year":"2012","unstructured":"Mehta RH, Yu J, Piccini JP, Tcheng JE, Farkouh ME, Reiffel J, Fahy M, Mehran R, Stone GW. Prognostic significance of postprocedural sustained ventricular tachycardia or fibrillation in patients undergoing primary percutaneous coronary intervention (from the HORIZONS-AMI Trial). Am J Cardiol. 2012;109(6):805\u201312.","journal-title":"Am J Cardiol"},{"issue":"2","key":"2635_CR6","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s40618-015-0354-z","volume":"39","author":"A Mantovani","year":"2016","unstructured":"Mantovani A, Rigolon R, Pichiri I, Pernigo M, Bergamini C, Zoppini G, Bonora E, Targher G. Hyperuricemia is associated with an increased prevalence of atrial fibrillation in hospitalized patients with type 2 diabetes. J Endocrinol Investig. 2016;39(2):159\u201367.","journal-title":"J Endocrinol Investig"},{"issue":"1","key":"2635_CR7","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1515\/cclm-2015-0523","volume":"54","author":"F Braga","year":"2016","unstructured":"Braga F, Pasqualetti S, Ferraro S, Panteghini M. Hyperuricemia as risk factor for coronary heart disease incidence and mortality in the general population: a systematic review and meta-analysis. Clin Chem Lab Med. 2016;54(1):7\u201315.","journal-title":"Clin Chem Lab Med"},{"issue":"8","key":"2635_CR8","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1161\/CIRCULATIONAHA.107.703389","volume":"116","author":"HK Choi","year":"2007","unstructured":"Choi HK, Curhan G. Independent impact of gout on mortality and risk for coronary heart disease. Circulation. 2007;116(8):894\u2013900.","journal-title":"Circulation"},{"issue":"1","key":"2635_CR9","doi-asserted-by":"publisher","first-page":"R10","DOI":"10.1186\/ar3684","volume":"14","author":"E Krishnan","year":"2012","unstructured":"Krishnan E, Pandya BJ, Lingala B, Hariri A, Dabbous O. Hyperuricemia and untreated gout are poor prognostic markers among those with a recent acute myocardial infarction. Arthritis Res Ther. 2012;14(1):R10.","journal-title":"Arthritis Res Ther"},{"issue":"17","key":"2635_CR10","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1056\/NEJMra0800885","volume":"359","author":"DI Feig","year":"2008","unstructured":"Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med. 2008;359(17):1811\u201321.","journal-title":"N Engl J Med"},{"key":"2635_CR11","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s12872-015-0089-y","volume":"15","author":"GZ Sun","year":"2015","unstructured":"Sun GZ, Guo L, Wang J, Ye N, Wang XZ, Sun YX. Association between hyperuricemia and atrial fibrillation in rural China: a cross-sectional study. BMC Cardiovasc Disord. 2015;15:98.","journal-title":"BMC Cardiovasc Disord"},{"issue":"9","key":"2635_CR12","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1016\/j.amjcard.2011.06.043","volume":"108","author":"L Tamariz","year":"2011","unstructured":"Tamariz L, Agarwal S, Soliman EZ, Chamberlain AM, Prineas R, Folsom AR, Ambrose M, Alonso A. Association of serum uric acid with incident atrial fibrillation (from the Atherosclerosis Risk in Communities [ARIC] study). Am J Cardiol. 2011;108(9):1272\u20136.","journal-title":"Am J Cardiol"},{"issue":"4","key":"2635_CR13","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.amjcard.2013.04.012","volume":"112","author":"F Valbusa","year":"2013","unstructured":"Valbusa F, Bertolini L, Bonapace S, Zenari L, Zoppini G, Arcaro G, Byrne CD, Targher G. Relation of elevated serum uric acid levels to incidence of atrial fibrillation in patients with type 2 diabetes mellitus. Am J Cardiol. 2013;112(4):499\u2013504.","journal-title":"Am J Cardiol"},{"issue":"4","key":"2635_CR14","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.ejim.2015.02.007","volume":"26","author":"AF Cicero","year":"2015","unstructured":"Cicero AF, Rosticci M, Tocci G, Bacchelli S, Urso R, D\u2019Addato S, Borghi C. Serum uric acid and other short-term predictors of electrocardiographic alterations in the Brisighella Heart Study cohort. Eur J Intern Med. 2015;26(4):255\u20138.","journal-title":"Eur J Intern Med"},{"issue":"2","key":"2635_CR15","doi-asserted-by":"publisher","first-page":"101","DOI":"10.5387\/fms.58.101","volume":"58","author":"S Yamada","year":"2012","unstructured":"Yamada S, Suzuki H, Kamioka M, Kamiyama Y, Saitoh S, Takeishi Y. Uric acid increases the incidence of ventricular arrhythmia in patients with left ventricular hypertrophy. Fukushima J Med Sci. 2012;58(2):101\u20136.","journal-title":"Fukushima J Med Sci"},{"issue":"11","key":"2635_CR16","first-page":"e898","volume":"17","author":"F Gragnano","year":"2021","unstructured":"Gragnano F, Spirito A, Corpataux N, Vaisnora L, Galea R, Gargiulo G, Siontis GCM, Praz F, Lanz J, Billinger M, et al. Impact of clinical presentation on bleeding risk after percutaneous coronary intervention and implications for the ARC-HBR definition. EuroIntervention J EuroPCR Collab Work Group Interv Cardiol Eur Soc Cardiol. 2021;17(11):e898\u2013909.","journal-title":"EuroIntervention J EuroPCR Collab Work Group Interv Cardiol Eur Soc Cardiol"},{"issue":"20","key":"2635_CR17","first-page":"2506","volume":"33","author":"J Taylor","year":"2012","unstructured":"Taylor J. Third universal definition of myocardial infarction. Eur Heart J. 2012;33(20):2506\u20137.","journal-title":"Eur Heart J"},{"issue":"4","key":"2635_CR18","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.jacc.2009.03.054","volume":"54","author":"G Niccoli","year":"2009","unstructured":"Niccoli G, Burzotta F, Galiuto L, Crea F. Myocardial no-reflow in humans. J Am Coll Cardiol. 2009;54(4):281\u201392.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"2635_CR19","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/0021-9681(86)90069-X","volume":"39","author":"CJ McDonald","year":"1986","unstructured":"McDonald CJ, Hui SL, Tierney WM. Diuretic-induced laboratory abnormalities that predict ventricular ectopy. J Chronic Dis. 1986;39(2):127\u201335.","journal-title":"J Chronic Dis"},{"issue":"1","key":"2635_CR20","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s12916-017-0816-6","volume":"15","author":"JA Singh","year":"2017","unstructured":"Singh JA, Cleveland J. Allopurinol and the risk of ventricular arrhythmias in the elderly: a study using US Medicare data. BMC Med. 2017;15(1):59.","journal-title":"BMC Med"},{"issue":"1","key":"2635_CR21","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.tcm.2018.06.004","volume":"29","author":"G Giannopoulos","year":"2019","unstructured":"Giannopoulos G, Angelidis C, Deftereos S. Gout and arrhythmias: In search for causation beyond association. Trends Cardiovasc Med. 2018;29:41\u20137.","journal-title":"Trends Cardiovasc Med"},{"issue":"10","key":"2635_CR22","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.recesp.2012.03.027","volume":"65","author":"B Benito","year":"2012","unstructured":"Benito B, Josephson ME. Ventricular tachycardia in coronary artery disease. Revista espanola de cardiologia (English ed). 2012;65(10):939\u201355.","journal-title":"Revista espanola de cardiologia (English ed)"},{"issue":"7","key":"2635_CR23","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/S0002-9149(00)00692-5","volume":"85","author":"L Mark","year":"2000","unstructured":"Mark L, Katona A. Effect of fluvastatin on QT dispersion: a new pleiotropic effect? Am J Cardiol. 2000;85(7):919\u201320.","journal-title":"Am J Cardiol"},{"key":"2635_CR24","doi-asserted-by":"publisher","first-page":"9656078","DOI":"10.1155\/2016\/9656078","volume":"2016","author":"AA Sovari","year":"2016","unstructured":"Sovari AA. Cellular and molecular mechanisms of arrhythmia by oxidative stress. Cardiol Res Pract. 2016;2016:9656078.","journal-title":"Cardiol Res Pract"},{"issue":"3","key":"2635_CR25","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1161\/hh1501.094115","volume":"89","author":"D Cesselli","year":"2001","unstructured":"Cesselli D, Jakoniuk I, Barlucchi L, Beltrami AP, Hintze TH, Nadal-Ginard B, Kajstura J, Leri A, Anversa P. Oxidative stress-mediated cardiac cell death is a major determinant of ventricular dysfunction and failure in dog dilated cardiomyopathy. Circ Res. 2001;89(3):279\u201386.","journal-title":"Circ Res"},{"issue":"4","key":"2635_CR26","doi-asserted-by":"publisher","first-page":"337","DOI":"10.2459\/JCM.0000000000000926","volume":"21","author":"A Mandurino-Mirizzi","year":"2020","unstructured":"Mandurino-Mirizzi A, Demarchi A, Ruffinazzi M, Cornara S, Somaschini A, Crimi G, Ferlini M, Camporotondo R, Gnecchi M, Ferrario M, et al. Serum uric acid may modulate the inflammatory response after primary percutaneous coronary intervention in patients with ST-elevation myocardial infarction. J Cardiovasc Med (Hagerstown). 2020;21(4):337\u20139.","journal-title":"J Cardiovasc Med (Hagerstown)"},{"issue":"1","key":"2635_CR27","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.jphs.2016.03.009","volume":"131","author":"TM Lee","year":"2016","unstructured":"Lee TM, Lin SZ, Chang NC. Effects of urate-lowering agents on arrhythmia vulnerability in post-infarcted rat hearts. J Pharmacol Sci. 2016;131(1):28\u201336.","journal-title":"J Pharmacol Sci"},{"issue":"3 Pt 2","key":"2635_CR28","first-page":"H805","volume":"260","author":"LS Terada","year":"1991","unstructured":"Terada LS, Rubinstein JD, Lesnefsky EJ, Horwitz LD, Leff JA, Repine JE. Existence and participation of xanthine oxidase in reperfusion injury of ischemic rabbit myocardium. Am J Physiol. 1991;260(3 Pt 2):H805-810.","journal-title":"Am J Physiol"},{"issue":"3","key":"2635_CR29","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1161\/01.RES.67.3.770","volume":"67","author":"JW de Jong","year":"1990","unstructured":"de Jong JW, van der Meer P, Nieukoop AS, Huizer T, Stroeve RJ, Bos E. Xanthine oxidoreductase activity in perfused hearts of various species, including humans. Circ Res. 1990;67(3):770\u20133.","journal-title":"Circ Res"},{"issue":"4","key":"2635_CR30","doi-asserted-by":"publisher","DOI":"10.1111\/eci.13719","volume":"52","author":"X Hu","year":"2022","unstructured":"Hu X, Yang X, Li X, Li G, Zhou Y, Dong H. Elevated uric acid is related to the no-\/slow-reflow phenomenon in STEMI undergoing primary PCI. Eur J Clin Investig. 2022;52(4): e13719.","journal-title":"Eur J Clin Investig"},{"issue":"5","key":"2635_CR31","doi-asserted-by":"publisher","first-page":"240","DOI":"10.2459\/JCM.0000000000000634","volume":"19","author":"A Mandurino-Mirizzi","year":"2018","unstructured":"Mandurino-Mirizzi A, Crimi G, Raineri C, Pica S, Ruffinazzi M, Gianni U, Repetto A, Ferlini M, Marinoni B, Leonardi S, et al. Elevated serum uric acid affects myocardial reperfusion and infarct size in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. J Cardiovasc Med (Hagerstown). 2018;19(5):240\u20136.","journal-title":"J Cardiovasc Med (Hagerstown)"},{"issue":"41","key":"2635_CR32","doi-asserted-by":"publisher","first-page":"2793","DOI":"10.1093\/eurheartj\/ehv316","volume":"36","author":"SG Priori","year":"2015","unstructured":"Priori SG, Blomstr\u00f6m-Lundqvist C, Mazzanti A, Blom N, Borggrefe M, Camm J, Elliott PM, Fitzsimons D, Hatala R, Hindricks G, et al. ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: the Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J. 2015;36(41):2793\u2013867.","journal-title":"Eur Heart J"},{"issue":"2","key":"2635_CR33","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1093\/eurheartj\/ehx393","volume":"39","author":"B Ibanez","year":"2018","unstructured":"Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, Caforio ALP, Crea F, Goudevenos JA, Halvorsen S, et al. 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39(2):119\u201377.","journal-title":"Eur Heart J"},{"issue":"3","key":"2635_CR34","doi-asserted-by":"publisher","first-page":"M178","DOI":"10.1093\/gerona\/57.3.M178","volume":"57","author":"WS Aronow","year":"2002","unstructured":"Aronow WS, Ahn C, Mercando AD, Epstein S, Kronzon I. Prevalence and association of ventricular tachycardia and complex ventricular arrhythmias with new coronary events in older men and women with and without cardiovascular disease. J Gerontol A Biol Sci Med Sci. 2002;57(3):M178-180.","journal-title":"J Gerontol A Biol Sci Med Sci"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-022-02635-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12872-022-02635-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-022-02635-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T00:02:38Z","timestamp":1727049758000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccardiovascdisord.biomedcentral.com\/articles\/10.1186\/s12872-022-02635-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,26]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2635"],"URL":"https:\/\/doi.org\/10.1186\/s12872-022-02635-4","relation":{},"ISSN":["1471-2261"],"issn-type":[{"type":"electronic","value":"1471-2261"}],"subject":[],"published":{"date-parts":[[2022,4,26]]},"assertion":[{"value":"21 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All methods were carried out in accordance with relevant guidelines and regulations. Written informed consent was obtained from individual or guardian participants. This study followed the principles outlined in the Declaration of Helsinki. The protocals was approved by Institutional Ethics Committee of Jinhua Municipal Central Hospital.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"199"}}